IMRX stock forecast, quote, news & analysis
Immuneering Corp is a biopharmaceutical company... Show more
Why Immuneering (IMRX) Stock Is Down -15.8% in the Last 30 Days
Key Takeaways
- Immuneering (IMRX) shares have declined roughly 15.8% over the trailing 30 days, from a closing price of about $4.48 in mid-September to approximately $3.77.
- The pullback has occurred despite no major negative clinical or regulatory news, suggesting technical and sentiment-driven pressure rather than a fundamental setback.
- Over the trailing quarter, the stock is down about 12%, giving back a portion of the strong gains it posted during the first half of 2026.
- The company's lead program, the oral MEK inhibitor atebimetinib, remains in a pivotal Phase 3 trial (MAPKeeper 301) in first-line pancreatic cancer.
- Immuneering ended the second quarter of 2026 with $182.7 million in cash and equivalents and a projected runway into 2029.
Immuneering (IMRX) Company Overview and Market Position
Immuneering Corporation is a late-stage clinical oncology company focused on cancers driven by RAS, RAF, and other MAPK pathway mutations. Its core scientific approach is built around a proprietary class of medicines the company calls Deep Cyclic Inhibitors, which are designed to deliver durable tumor suppression while minimizing the chronic toxicity historically associated with MEK inhibitors.
The company's lead candidate, atebimetinib (formerly IMM-1-104), is an oral, once-daily MEK inhibitor currently in a global randomized pivotal Phase 3 trial known as MAPKeeper 301, evaluating the drug in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer. Investors follow IMRX closely because of the sizable pancreatic cancer opportunity, the drug's promising Phase 2a survival data, and the company's balance-sheet strength relative to many pre-revenue peers.
Immuneering (IMRX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, IMRX has moved lower. The stock closed near $4.48 in mid-September and has since declined to roughly $3.77, a drop of approximately 15.8%. The move has been gradual rather than event-driven, with the shares trending down through late September and October.
Looking at the trailing quarter, the picture is similar but slightly less severe. From a closing level of about $4.29 in mid-July, the stock has fallen roughly 12% to its current level. That quarterly decline is more notable when measured against the stock's mid-August closing high near $5.33, from which the shares have retreated about 29%, indicating that much of the recent weakness reflects a steady unwinding of gains accumulated earlier in the year.
What Drove IMRX Stock Price in the Last 30 Days
The recent decline has not been tied to a specific negative clinical data readout, regulatory setback, or financing event. Instead, the move appears to reflect a combination of profit-taking and waning momentum in a pre-revenue biotech with no near-term binary catalyst.
Several company developments during the period were neutral to positive. Immuneering announced presentations at the AACR Conference on Pancreatic Cancer and a trial-in-progress abstract for the Phase 3 MAPKeeper 301 study at the ESMO Congress 2026, both highlighting the company's continued execution on its clinical plan. The absence of a clear fundamental trigger behind the decline points to broader factors, including pressure on small-cap and clinical-stage biotechnology names and a period of consolidation following the stock's first-half 2026 run-up. With the next major data readout (Phase 3 topline) not expected until mid-2028, traders may have reduced positioning in the absence of a fresh catalyst.
What Drove IMRX Stock Performance Over the Last Quarter
Over the broader multi-month period, IMRX's performance reflects a rally that outpaced fundamentals followed by a cooling-off phase. The company began dosing patients in its pivotal Phase 3 MAPKeeper 301 trial in June 2026 and presented a 17.3-month median overall survival figure from its Phase 2a study in first-line pancreatic cancer, events that supported investor enthusiasm earlier in the year.
In August, H.C. Wainwright initiated coverage with a Buy rating and a $14 price target, while other analysts maintained constructive views, contributing to a mid-August peak above $5.30. However, as clinical-stage biotech sentiment softened and the stock lacked an immediate catalyst to sustain its valuation, the shares gradually drifted lower through the remainder of the quarter. The appointment of a new CFO and the reporting of a solid second-quarter cash position provided fundamental support but were not enough to reverse the technical downtrend.
Trending AI Robots
For traders seeking a more systematic approach, Tickeron's Trending AI Robots page offers a curated view of top-performing algorithmic trading strategies. Tickeron provides hundreds of AI-powered trading bots that monitor thousands of tickers, but only the most relevant and best-performing bots are featured in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to compare approaches that suit different trading styles and risk tolerances. Exploring the section can help traders identify automated strategies that align with their objectives.
IMRX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important catalysts for IMRX will be clinical and execution-driven. Investors should monitor progress on enrollment and any interim updates from the Phase 3 MAPKeeper 301 trial, the initiation of the planned Phase 2 lung cancer study of atebimetinib in combination with an anti-PD-1 therapy, and the preliminary data readout expected in late 2027. Additional preclinical data presentations, including material scheduled for the fourth quarter of 2026, could also shape sentiment.
On the financial side, the company's cash runway into 2029 reduces near-term dilution risk but does not eliminate it, and ongoing cash burn will remain a key metric. Broader factors, including small-cap biotech sentiment, sector fund flows, and interest-rate expectations, may also continue to influence the stock in the near term.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IMRX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 38 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Indicator exited the oversold zone, 25 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 59 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on IMRX as a result. In 80 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 224 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMRX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.292) is normal, around the industry mean (2.973). P/E Ratio (-4.097) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology